Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01170663 · OUTCOME

Cmax After 4th Ramucirumab (IMC-1211B) Infusion

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma · Source last updated 2019-09-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
µg/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)

Analysis population: All participants who received Ramucirumab (IMC-1121B) plus Paclitaxel and had Cmax observations at specific timepoint.

Groups in this outcome

Ramucirumab (IMC-1211B) Plus Paclitaxel

8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ramucirumab (IMC-1211B) Plus Paclitaxel200

Reported measurements

Source class 1
Values in µg/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Ramucirumab (IMC-1211B) Plus Paclitaxel19334Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        34
        value
        193
denoms
  1. counts
    1. group Id
      OG000
      value
      200
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.
    id
    OG000
    title
    Ramucirumab (IMC-1211B) Plus Paclitaxel
param Type
GEOMETRIC_MEAN
population Description
All participants who received Ramucirumab (IMC-1121B) plus Paclitaxel and had Cmax observations at specific timepoint.
reporting Status
POSTED
time Frame
Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)
title
Cmax After 4th Ramucirumab (IMC-1211B) Infusion
type
SECONDARY
unit Of Measure
µg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice